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Abstract 
Boldione (1,4-androstadiene-3,17-dione) is included in the list of prohibited substances, 
issued by  the World Antidoping Agency, in the group of exogenous anabolic steroids. 
Endogenous production of low concentrations of boldione has also been reported. The 
objective of the study was to assess boldione metabolism in humans.  Detection of 
boldione metabolites was accomplished by analysis by liquid chromatography coupled 
to tandem mass spectrometry of urine samples obtained after administration of the drug 
and subjected to different sample preparation procedures to analyze the different 
metabolic fractions.  In addition to boldione, eight metabolites were detected in the free 
fraction. Three of them were identified by comparison with standards: androsta-1,4,6-
triene-3,17-dione (M5), (5α)-1-androstenedione (M6)- and (5α)-1-testosterone (M8). 
Metabolite M7 was identified as the 5β-isomer of 1-androstenedione, and metabolites 
M1 to M4 were hydroxylated metabolites and tentative structures were proposed based 
on mass spectrometric data. After β-glucuronidase hydrolysis, five additional 
metabolites excreted only as conjugates with glucuronic acid were detected: boldenone, 
(5β)-1-testosterone (M9), and three metabolites resulting from reduction of the 3-keto 
group. In addition, four metabolites (M3, M4, M5, M6) increased their concentration in 
urine after treatment of the urine in alkaline conditions. Boldenone, epiboldenone, and 
hydroxylated metabolites of boldione, boldenone and 1-testosterone were detected as 
conjugates with sulphate. The longer detection time was observed for metabolite M4 
after alkaline treatment of the urine, which was detected up to 5 days after boldione 
administration. 
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Introduction 
The use of anabolic androgenic steroids (AAS) can increase muscular strength and lean 
body mass in athletes [1]. For this reason, they are included in list of prohibited 
substances yearly published by WADA [2]. AAS is the group of substances largely 
detected in the anti-doping control field [3]. Therefore, doping control laboratories have 
to develop analytical strategies suitable for the detection of their misuse. AAS are 
extensively metabolized in the human body and the parent drug, if present, is detected 
in urine at very low concentrations [4-6]. Thus, the urinary detection of AAS 
metabolites is normally used as marker for AAS misuse. In order to establish the best 
marker to be included in screening methods, metabolic studies are necessary [7].  
Metabolic studies of AAS were traditionally performed by gas chromatography coupled 
to mass spectrometry (GC-MS) [5,6,8]. The occurrence of liquid chromatography 
coupled to tandem mass spectrometry (LC-MS/MS) opened several alternatives for 
metabolic studies such as the use of precursor ion or neutral loss scan methods [9-11], 
and the possibility of the direct detection of phase II metabolites [12-15]. 
Boldione (1,4-androtadien-3,17-dione) is a prohormone marketed in preparations for 
human and animal consumption [16-18].  It is an orally active precursor of the AAS 
boldenone. For this reason, boldione misuse can be screened by detection of boldenone 
metabolites [6]. Boldione has also been found to be endogenous in humans at low 
concentrations [19]. In addition, boldione is released after alkaline treatment of the urine 
samples and its concentration is increased after testosterone administration, indicating 
that boldione results from a phase II metabolite of testosterone which is hydrolysed in 
alkaline conditions [20-21]. This phase II metabolite has been recently identified as a 
conjugate with cysteine [22]. 
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Limited data on boldione metabolism in humans has been published in the literature 
[6,16,23]. Using GC-MS, Uralets and Gillette [16] identified 5β-reduced metabolites 
excreted as glucuronoconjugates: 5β-androst-1-en-3α-ol-17-one as the major metabolite, 
(5β)-1-testosteronre, 5β-androst-1-en-3α,17β-diol and (5β)-1-androstenedione. These 
metabolites were also previously identified as metabolites of boldenone [24]. 
Hydroxylated boldione, 5β-androst-1-en-6β-ol-3,17-dione and another unidentified 
metabolite appeared after solvolysis of the sulphate conjugates [16]. Boldenone was not 
detected in that study. However in a second study using LC-MS/MS, boldione, 
boldenone, and two minor hydroxylated metabolites, not fully characterized, were 
described after administration of a boldione tablet to a healthy volunteer [23]. All these 
metabolites were detected in urine up to 48 h after administration of the drug. Boldione 
was also identified as a minor metabolite of boldenone, obtained after treatment of the 
urine with potassium carbonate [24]. 
The objective of this work was to study boldione metabolism by LC-MS/MS in order to 
take advantage of this technology for the detection and identification of new phase I and 
phase II metabolites that could improve the detection of boldione misuse. The 
developed methods for the detection of new metabolites have been developed and 
applied to samples from excretion studies. In the present paper, detection of metabolites 
excreted free, conjugated with glucuronic acid, with sulphate and metabolites released 
after alkaline treatment of the urines is described. In a second part of the study [25], the 
detection and characterization of metabolites of boldione conjugated with cysteine and 
N-acetylcisteine is described. 
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Experimental 
Chemicals and reagents 
1,4-adrostadien-3,17-dione (boldione), 5α-androst-1-en-3,17-dione ((5α)-1-
androstenedione), 5β-androst-1-en-17β-ol-3-one ((5β)-1-testosterone) and 17β-
hydroxy-androst-1-en-3-one ((5α)-1-testosterone) were obtained from NMI (Pymble, 
Australia). Androsta-1,4,6-triene-3,17-dione  was purchased from Steraloids, Inc. 
(Newport, RI, USA). 1,4-androstadien-17β-ol-3-one (boldenone)  and 17α-
methylandrost-4-en-17β-ol-3-one (methyltestosterone) were obtained from Sigma 
(Steinheim, Germany). 
Tert-butyl methyl ether (TBME, HPLC grade), ethyl acetate (HPLC grade), acetonitrile 
and methanol (LC gradient grade), formic acid (LC/MS grade), potassium carbonate, 
sulphuric acid, sodium hydroxide, di-sodium hydrogen phosphate, sodium hydrogen 
phosphate, sodium chloride, ammonia hydroxyde, ammonium chloride, and potassium 
hydroxyde (all analytical grade) were purchased from Merck (Darmstadt, Germany). 
Ammonium formate (HPLC grade) was obtained from Fluka, Sigma-Aldrich 
(Steinheim, Germany). β-glucuronidase from Escherichia coli was obtained from Roche 
Diagnostics (Mannheim, Germany). Milli Q water was obtained by a Milli-Q 
purification system (Millipore Ibérica, Barcelona, Spain).  
 
 Sample preparation 
Sample preparation procedures were applied to extract different metabolic fractions 
from the urine matrix. 
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1. Free fraction 
For the analysis of unconjugated fraction, 100 ng mL-1 of methyltestosterone (internal 
standard, ISTD) was added to urine samples (5 mL) and pH was adjusted by addition of 
250 µL of 25% K2CO3 solution. Liquid-liquid extraction was performed by adding 6 
mL of TBME and shaking at 40 mpm for 20 min. After centrifugation (3000 g, 5 min), 
the organic layers were separated and evaporated to dryness under a stream of nitrogen 
in a water bath at 40 ºC. The extracts were reconstituted with 100 μL of a mixture of 
deionized water:acetonitrile (50:50, v/v) and aliquots of 10 μL were analyzed by LC-
MS/MS. 
  
2. Combined fraction (free and glucuronide conjugates) 
100 ng mL-1 of methyltestosterone (ISTD) and 1 mL of sodium phosphate buffer (1 M, 
pH 7) were added to urine samples (5 mL). Enzymatic hydrolysis was performed by 
adding 30 µL of β-glucuronidase from E. coli and incubating the mixture at 55ºC for 1h. 
After the sample reached the ambient temperature, 250 µL of 5% K2CO3 solution was 
added and the mixture was extracted with 6 mL of TBME by shaking at 40 mpm for 20 
min. After centrifugation (3000 g, 5 min), the organic layers were separated and 
evaporated to dryness under a stream of nitrogen in a water bath at 40 ºC. The extracts 
were reconstituted with 100 μL of a mixture of deionized water:acetonitrile (50:50, v/v) 
and aliquots of 10 μL were analyzed by LC-MS/MS. 
 
3. Sulphated fraction 
Sulphate conjugated metabolites were directly extracted from the urine samples using a 
liquid-liquid procedure described elsewhere [26]. 100 ng mL-1 of methyltestosterone 
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(ISTD) was added to urine samples (5 mL) and pH was alkalinized by addition of 100 
μL of a buffer (5.3 M ammonium chloride solution adjusted to pH 9.5 with ammonia 
hydroxide solution). Then, sodium chloride (1 g) was added to promote salting-out 
effect and the samples were extracted with 8 mL of ethyl acetate by shaking at 40 mpm 
for 20 min. After centrifugation (3000 g, 5 min), the organic layers were evaporated to 
dryness under a nitrogen stream in a water bath at 40 °C. The extracts were 
reconstituted with 100 μL of a mixture of deionized water:acetonitrile (90:10, v/v) and 
aliquots of 10 μL were analyzed by LC-MS/MS. 
 
4. Metabolites released after alkaline treatment 
Labile conjugated metabolites hydrolysed in alkaline conditions were extracted in 
conditions previously described [21].100 ng mL-1 of methyltestosterone (ISTD) was 
added to urine samples (5 mL) and were directly alkalinized by addition of 300 µL of 
KOH 6M (no previous enzymatic hydrolysis was performed). Incubation was perfo 
rmed during 15 minutes at 60 ºC. After cooling to room temperature, a liquid-liquid 
extraction was performed by addition of 6 mL TBME. After centrifugation (3000 g, 5 
min), the organic layers were evaporated to dryness under a nitrogen stream in a water 
bath at 40 °C. The extracts were reconstituted with 100 μL of a mixture of deionized 
water:acetonitrile (50:50, v/v) and aliquots of 10 μL were analyzed by LC-MS/MS. 
 
 LC-MS/MS analysis 
Chromatographic separations were carried out on a Waters Acquity UPLC™ system 
(Waters Corporation, Milford, MA) using an Acquity BEH C18 column (100 mm × 2.1 
mm i.d., 1.7 µm particle size). The column temperature was set to 55 °C. The mobile 
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phase consisted of deionized water with 1mM ammonium formate and 0.01% formic 
acid (solvent A) and methanol with 1mM ammonium formate and 0.01% formic acid 
(solvent B). Different gradient elution and flow-rates were used depending on the 
experiment and they are described in next paragraphs. The sample volume injected was 
always 10 µL. 
The LC instrument was coupled to a Quattro Premier XE triple quadrupole mass 
spectrometer (Micromass, Waters Corporation, Milford, MA) with an electrospray (Z-
spray) ionization source. Source conditions were fixed as follows: lens voltage, 0.2 V; 
source temperature 120 °C; desolvation temperature, 450 °C; cone gas flow rate, 50 L/h; 
desolvation gas flow rate, 1,200 L/h. In electrospray ionization (ESI) positive mode the 
capillary voltage was set at 3 kV, whereas in negative ESI mode the capillary voltage 
was set at 2.5 kV. High-purity nitrogen was used as desolvation gas and argon was used 
as collision gas. 
For the open detection of metabolites in the free and combined fractions  and 
metabolites released after alkaline treatment, the following gradient pattern was used: 
from 0 to 1.5 min, 30% B; from 1.5 to 8 min, to 55% B; from 8 to 15 min, 55% B; from 
15 to 29.5 min, to 95% B; during 1 min, 95% B; from 30.5 to 31 min, to 30% B; from 
31 to 34 min, 30% B, at a flow rate of 0.2 mL min−1. Data acquisition was performed in 
precursor ion scan (Method 1, Table 1). 
For the untargeted detection of sulphate conjugated metabolites, the gradient elution 
was as follow: from 0 to 0.5 min, 15% B; from 0.5 to 9 min, to 50% B; from 9 to 14 
min, 50% B; from 14 to 16.4 min, to 90% B; from 16.4 to 17 min, 90% B; from 17 to 
17.5 min, to 15% B; from 17.5 to 20 min, 15% B at a flow rate of 0.2 mL min−1. Data 
acquisition was performed in precursor ion scan of ion at m/z 97 (Method 2, Table 1). 
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For the targeted detection of metabolites, the following gradient pattern was used: from 
0 to 0.6 min, 30% B; from 0.6 to 5 min, to 55% B; from 5 to 7 min, 55% B; from 7 to 
11 min, to 95% B; from 11 to 12 min, 95% B; from 12 to 12.3 min, to 30% B; from 
12.3 to 15 min, 15% B at a flow rate of 0.3 mL min−1. Data acquisition was performed 
in selected reaction monitoring (SRM) (Table 2). 
  
Excretion study samples  
Urine samples obtained from an excretion study involving the administration of a single 
dose of 200 mg boldione to a healthy volunteer were obtained. The clinical protocol was 
approved by the Local Ethical committee (CEIC-IMAS, Institut Municipal 
d’Assistència Sanitària, Barcelona, Spain). The urine samples were collected before 
administration (3 samples) and up to 15 days after administration at the following 
periods: 0-2h, 2-3h, 3-6h, 8-10h, 10-12h, 12-24h; spot urines at 26h, 30h, 32h, 36h, 38h, 
and 72h; and daily spot morning urines from days 5 to 15 after administration. Urine 
samples were stored at -20 ºC until analysis. 
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Results and discussion 
 
1. Detection and characterization of metabolites excreted free and conjugated 
with glucuronic acid 
Detection of boldione metabolites was accomplished by analysis by LC-MS/MS of 
urine samples obtained after administration of the drug and subjected to different 
sample preparation procedures to analyze the different metabolic fractions. MS/MS 
methods based on precursor ion scan of ions m/z 77, 91 and 105 in positive mode were 
applied to detect metabolites excreted in free fraction, in the combined fraction (free and 
glucuronide conjugates) and in the fraction of metabolites released after alkaline 
treatment. Precursor ion scan of ions m/z 77, 91 and 105 allow for the detection of 
compounds of steroidal nature [9-11]. After combining the information of all precursor 
ion scan methods, and contrasting the results between post- and pre-administration 
samples, different peaks were selected (Table 3). These peaks were considered as 
potential boldione metabolites. 
Regarding the free fraction (Table 3), in addition to unchanged boldione, eight potential 
metabolites were detected. In positive ion mode, all of them were ionized by formation 
of the [M+H]+ ion, indicating the presence of  a conjugated 3-keto function [9]. Some of 
the metabolites were identified by comparison with standards: metabolite M5, androsta-
1,4,6-triene-3,17-dione; metabolite M6, (5α)-1-androstenedione; and metabolite M8, 
(5α)-1-testosterone. For the rest of metabolites no standard was available. 
After analysis of the combined fraction, which includes compounds excreted in free 
form and compounds excreted as glucuronoconjugates, five additional metabolites not 
previously detected in the free fraction were detected (Table 3). Thus, these additional 
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metabolites are only excreted as conjugates with glucuronic acid.  Two of the 
metabolites, boldenone and metabolite M9 ((5β)-1-testosterone) were identified by 
comparison of the analytical data with pure standards of the compounds. These two 
metabolites are the main boldenone metabolites in humans and it has been described 
that they are mainly excreted as glucuronoconjugates [24]. Boldenone and metabolite 
M9 were ionized by formation of the [M+H]+ ion. However, for metabolites M10, M11 
and M12 the ion [M+H-H20]+ was formed instead of the ion [M+H]+, indicating that the 
conjugated 3-keto function is not present in their structures [9] (Table 3). 
Structures of some of the metabolites have been confirmed by comparison of the data 
obtained in excretion study samples with pure standards of the metabolites. For 
metabolites not available as standards, structures have been proposed based on LC-
MS/MS analysis using product ion scan methods. The ions produced for each 
metabolite were compared with those obtained for the parent drug and the commercially 
available metabolites. For confirmation of these structures, the use of pure standards 
will be mandatory. The structures of the metabolites detected are depicted in Figure 1 
and collision induced dissociation (CID) mass spectra of [M+H]+ ion of the metabolites 
are shown in Figures 2 and 3.  
In Figure 2, CID mass spectra of the metabolites available as standards are presented. 
Spectra of boldione and boldenone are governed by a product ion at m/z 121, formed by 
cleavage in the B ring and characteristic of 1,4-diene-3-keto structure [27,28]. CID mass 
spectra of androsta-1,4,6-triene-3,17-dione (M5) is dominated by the ion at m/z 147, 
characteristic of steroids with a double bond in position 6. On the other hand, 
metabolites with 1-ene-3-keto structure (M6, M8 and M9) showed a characteristic loss 
of 84 Da (m/z 203 for M6; m/z 205 for M8 and M9), an additional loss of water 
(102Da, m/z 185 for M6, and m/z 187 for M8 and M9) [29,30].   
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Metabolites M2 and M3 
The MM of metabolites M1 and M2 is 302 Da. This indicates for the M1 a double 
hydroxylation and for the M2 a reduction and subsequent hydroxylation , with respect 
to boldione.  Identical product ion mass spectra were obtained for both compounds 
suggesting that they are isomers (Figure 3). The presence of ion at m/z 121 as the base 
peak, confirms the existence of a 1,4-diene-3-keto structure, as for boldione and 
boldenone. Therefore, the reduction has to occur in the 17-keto group to form a 17-
hydroxy-metabolite.  
The mass spectrometric data does not indicate the position of the additional hydroxyl 
group. However, taking into consideration the normal metabolic pathways for anabolic 
steroids [4], hydroxylation in C16 is one of the most feasible possibilities (Figure 1). 
 
Metabolite M4 
The MM of metabolite M4 is 300 Da, indicating an hydroxylation with respect to 
boldione. In addition to [M+H]+ ion, another ion at m/z 283 ([M+H-H2O]+ was 
observed in the MS spectra. In the CID spectrum of [M+H]+ ion (Figure 3) , the product 
ion at m/z 121 is not the base peak, indicating that one of the hydroxyl groups is 
incorporated in the A or B rings. 6β-hydroxylation is one of the common metabolic 
transformations of compounds of steroidal nature [4], and a 6β-hydroxy-metabolite 
(androst-1,4-diene-6β-ol-3,17-dione) was identified as boldenone metabolite [24]. 
Therefore, the most feasible structure for metabolite M4 is androst-1,4-diene-6β-ol-
3,17-dione (Figure 1).   
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Metabolite M1 
The MM of metabolite M1 is 316 Da, suggesting the addition of two hydroxyl groups. 
As for metabolite M4, ion at m/z 121 is not the base ion of the MS/MS spectrum 
(Figure 3), indicating that one of the hydroxyl groups is incorporated in the A or B 
rings, probably in C6. The position of the second hydroxyl group could not be proposed 
based on mass spectrometric data available (Figure 1). However,  as indicated for 
metabolites M2 and M3, taking into consideration the normal metabolic pathways for 
anabolic steroids [4], hydroxylation in C16 is one of the most feasible possibilities 
(Figure 1). Therefore, androst-1,4-diene-6β,16-diol-3,17-dione is the proposed structure 
for metabolite M1. 
 
Metabolites M6 and M7 
Metabolites M6 and M7 have a similar mass spectrum indicating that they are isomers 
(Figures 2 and 3). M6 was identified as (5α)-1-androstenedione by comparison with a 
standard. Therefore, metabolite M7 is proposed to be (5β)-1-androstenedione. 
Metabolite M7 was also described by Uralets and Gillette [14] as boldione metabolite.  
Both metabolites were identified by Schanzer et al [21] after alkaline treatment of the 
urines obtained after boldenone administration.  
 
Metabolites M10, M11 and M12 
As indicated above, for metabolites M10, M11 and M12 the ion [M+H-H20]+ was 
formed and the ion [M+H]+ was not present, indicating that the conjugated 3-keto 
function is not present in the structure of the metabolites.  Metabolites M10 and M11 
have a MM of 288 Da, indicating two reductions with respect to boldione. Identical 
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product ion mass spectra were obtained for both compounds suggesting that they are 
isomers (Figure 3). Because the conjugated 3-keto function is not present, reductions in 
3-keto group and ∆4 are suggested (Figure 1). 
Metabolite M12 has a MM of 290 Da, indicating an additional reduction with respect to 
metabolites M10 and M11. Additional reduction of the 17-keto group is proposed 
(Figure 1). 
Metabolites M10-M12 were described by other authors either after administration of 
boldione [16] and also after administration of boldenone [24]. 
 
2. Metabolites released after alkaline treatment 
It was seen that four of the metabolites detected in the free fraction (M3, M4, M5, M6) 
increased their concentration in urine after treatment of the urine in alkaline conditions 
(Table 3). It has been recently demonstrated that labile conjugates of testosterone 
hydrolyzed in alkaline conditions are conjugates with cysteine or N-acetylcysteine [22]. 
The formation of these conjugates implies the conjugation with glutathione of a phase I 
metabolite with a polyunsaturated carbonyl group, and subsequent transformation to 
cysteine or N-acetylcysteine conjugates in urine.  According to the characterization 
performed, metabolites M3, M4, M5 and M6 bear in their structure a polyunsaturated 
carbonyl group (Figure 1). So, they have the adequate structure for conjugation with 
glutathione. Therefore, according to our results, metabolites M3, M4, M5 and M6 are 
excreted in free form and also as conjugates with cysteine or N-acetylcisteine. 
Characterization of these conjugates is described in the second part of our study on 
boldione metabolism [25]. 
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3. Metabolites excreted as conjugates with sulphate 
For the detection of metabolites conjugated with sulphate, a precursor ion scan method 
of ion at m/z 97 in negative mode was applied. Ion at m/z 97 is the hydrogensulphate 
anion, and it is common to all steroid sulphates in negative mode [12,31]. After 
combining the information between pre and post-administration samples, seven 
sulphated metabolites were considered as potential boldione metabolites (Table 4). 
Boldenone sulphate was identified by comparison with a pure standard.  Additionally, 
epiboldenone (M13) sulphate was identified using analytical data of a previous study of 
our group dealing with boldenone metabolism [12]. Boldenone and epiboldenone 
sulphates have been recently described as minor metabolites of boldenone in humans 
[12]. 
Product ion scan spectra in negative mode of steroid sulphates are characterized by the 
presence of only one ion at m/z 97, no other ions that could help on structural 
elucidation are formed [12]. For this reason, only tentative structures could be proposed 
for the other five metabolites, taking into consideration the molecular masses of the 
peaks detected, as indicated in Table 4. Thus, one hydroxylated metabolite of boldione 
(M4), epiboldenone (M13), two hydroxylated metabolites of boldenone (M2 and M3) 
and one hydroxylated metabolite of 1-testosterone (M14) are excreted as a sulphate 
conjugates. The formation of hydroxylated metabolites of boldione excreted in the 
sulphated fraction was also described by Uralets and Gillette [16]. 
 
 
 
4. Phase I metabolites of boldione 
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In Figure 1, a complete profile of all phase I metabolites characterized for boldione in 
the present study is presented. These metabolites were detected in free form, and 
conjugated with glucuronic acid, with cysteime or N-acetylcisteine, or with sulphate. 
Main metabolic pathways are: reduction in 17-keto group, 3-keto group or in ∆4; 
hydroxylations, probably in C6 and C16; and 6,7-dehydrogenation. Reduction of the 17-
ketone function results in boldenone and epiboldenone (M13). Epiboldenone was only 
detected as conjugated with sulphate. Boldenone is further hydroxylated to metabolites 
M2 and M3.  
Reduction in ∆4 of boldione resuts in the formation of 5α and 5β-isomers of 1-
androstenedione ((5α)-1-androstenedione, M6, and (5β)-1-androstenedione, M7).  
Further reductions of the 17-keto group of M6 and M7 produce (5α)-1-testosterone 
(M8) and (5β)-1-testosterone (M9), respectively. 
1-testosterone is also formed through the reduction of boldenone in ∆4. However, 
according to data described in the literature for boldenone metabolism [24], only the 5β-
isomer (M9) is produced. Hydroxylation of 1-testosterone results in the formation of 
metabolite M14, only excreted as conjugate with sulphate. 
Reduction of boldione in ∆4 and 3-keto forms metabolites M10, M11 and M12, only 
excreted as conjugates with glucuronic acid. Finally, 6,7-dehydrogenation results in the 
formation of androsta-1,4,6-triene-3,17-dione. 
Some of the metabolites (M3,M4, M5 and M6) are excreted as conjugates with cysteine 
or N-acetylcysteine [25]. 
 
5. Detection times   
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An SRM method was developed to monitor all metabolites in urine samples (Table 2). 
The method was found to be selective for all the selected analytes as no interferences 
were found in any of three blank samples analyzed. Urine samples collected up to 15 
days after the administration of an oral dose of boldione to a healthy volunteer were 
analyzed using the SRM method to evaluate the excretion profiles of the metabolites 
and their detection times.  
Detection times of each metabolite are listed in Tables 3 and 4. Some of the metabolites 
were detected only for few hours after administration (M2, M12). Others were detected 
up to 72h after administration (M6, M8 in the free fraction; boldenone, M9 and M11 
excreted as glucuronoconjugates; M3, M5 and M6, excreted as conjugates with cysteine 
or N-acetylcysteine; and boldenone, epiboldenone and hydroxy-boldenone sulphates), 
and the longest detection was obtained with metabolite M4. This metabolite was 
detected in the free fraction up to 38 h after administration, and in samples treated in 
alkaline conditions it was detected up to 5 days (Table 3). Therefore, metabolite M4 is 
mainly excreted as a conjugate with cysteine or N-acetylcysteine [25]. An example of 
the detection of metabolite M4 is given in Figure 4, where chromatograms of the free 
fraction and the fraction obtained after alkaline treatment in pre-administration samples 
and samples obtained 2 and 5 days after administration are presented. A peak of 
metabolite M4 is detected in the sample collected 5 days after administration treated in 
alkaline conditions. 
Boldione is normally detected by monitoring the main boldenone metabolites 
(boldenone and metabolite M9) excreted in the glucuronoconjugated fraction [24]. In 
our excretion study, these metabolites were detected up to 72h after administration. 
Therefore, the use of metabolite M4 as a marker of boldione use can significantly 
increase the retrospectivity of the detection.  
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Conclusion 
Boldione metabolites have been studied in different metabolic fractions. In addition to 
boldione, eight metabolites were detected in the free fraction resulting from 
hydroxylations (metabolites M1 to M4), 6,7-dehydrogenation (metabolite M5), and 
reduction in ∆4 (metabolites M6 and M7) and further reduction of the 17-keto group 
(metabolites M8 and M9). Five metabolites were detected only as glucuronoconjugates: 
boldenone and its main metabolite (metabolite M9) and three metabolites resulting from 
reduction in ∆4and 3-keto function (metabolites M10 to M12). From all these 
metabolites, six were not previously described for boldione. 
In addition, metabolites M3 to M6 increased their concentration after alkaline treatment 
of the urine indicating that they are also excreted as conjugates with cysteine or N-
acetylcysteine. These conjugates were not described before for boldione. Finally, seven 
metabolites were excreted as sulphate conjugates and only one was described 
previously. In summary, the use of LC-MS/MS has allowed the identification of new 
phase I and phase II metabolites of boldione.  In our excretion study, the longest 
restrospectivity was obtained for metabolite M4 excreted as conjugate with cysteine or 
N-acetylcysteine , which could be detected after 5 days of boldione administration.  
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Tables 
 
Table 1. Precursor ion scan methods. 
 
 Precursor ion (m/z) ESI CV (V) CE (eV) 
Mass range 
(m/z) 
Method 1 
77 + 25 50 250-400 
91 + 25 45 250-400 
105 + 25 45 250-400 
Method 2 97 - 60 30 350-475 
 
 
Table 2. SRM method (cone voltage, CV; collision energy, CE) and retention times 
(RT) of the metabolites detected.  
 
Metabolite RT (min) ESI 
Precursor ion 
(m/z) 
Product ion 
(m/z) 
CV 
(V) 
CE 
(eV) 
Boldione 6,1 + 285 121 30 25 
Boldenone 6,7 + 287 121 30 25 
M1 4,5 + 317 121 30 25 
M2, M3 3,4/3,7 + 303 121 30 25 
M4 4,1 + 301 121 30 20 283 97 30 25 
Androsta-1,4,6-triene-3,17-dione (M5) 5,9 + 283 97 30 25 
(5α)-1-androstenedione (M6) 8,0 + 287 185 30 25 
(5β)-1-androstenedione (M7) 8,2 + 287 185 30 25 
(5α)-1-testosterone (M8) 8,8 + 289 187 30 25 
(5β)-1-testosterone (M9) 8,9 + 289 187 30 25 
M10,M11 9/9,3 + 271 81 30 25 
M12 9,7 + 273 81 30 20 
Boldenone sulphate 4,9 - 365 350 60 30 
epiboldenone (M13) sulphate 5,4 - 365 350 60 30 
M4 sulphate 2,6/3,1 - 379 97 60 30 
M2,M3 sulphates 3,8/4,3 - 381 80 60 30 
M14 sulphate 5,5 - 383 97 60 30 
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Table 3. Potential boldione metabolites detected in the free fraction (A), additional 
metabolites detected in the combined fraction (B), and metabolites which increase their 
concentration after alkaline treatment (C). Retention times (RT) were obtained with the 
gradient described for open detection of metabolites. 
 
Fraction Metabolite MM (Da) 
[M+H]+ RT 
(min) 
Detection 
time 
A 
M1 316 317 7,1 24h 
M2 302 303 5,9 10h 
M3 302 303 6,1 38h 
M4 300 301 4,1 38h 
Androsta-1,4,6-triene-3,17-dione (M5) 282 283 9,3 38h  
Boldione 284 285 9,6 38h 
(5α)-1-androstenedione (M6) 286 287 12,5 72h 
(5β)-1-androstenedione (M7) 286 287 12,8 38h 
(5α)-1-testosterone (M8) 288 289 14,0 72h 
B 
Boldenone 286 287 10,4 72h 
(5β)-1-testosterone (M9) 288 289 14,7 72h 
M10 288 271* 16,8 38h 
M11 288 271* 18,1 72h 
M12 290 273* 18,9 8h 
C 
M3 302 303 6,1 72h 
M4 300 301 4,1 Day 5 
M5 282 283 9,3 72h 
M6 286 287 12,5 72h 
*For metabolites  M10 to M12, ion [M+H-H2O]+ was formed instead of [M+H]+ 
 
 
Table 4. Potential boldione metabolites excreted as conjugates with sulphate. Retention 
times (RT) were obtained with the gradient described for detection of sulphated 
metabolites. 
 
 
Metabolite MM (Da) [M-H]- RT (min) Detection time 
Boldenone sulphate 366 365 4,9 72h 
Epiboldenone (M13) sulphate 366 365 5,4 72h 
M4 sulphates 380 379 2,6 24h 380 379 3,1 26h 
M2, M3 sulphates 382 381 3,8 38h 382 381 4,3 72h 
M14 sulphate 384 383 5,5 36h 
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Figures 
 
Figure 1. Proposed metabolic profile regarding phase I metabolites for boldione. 
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Figure 2. Product ion mass spectra of [M+H]+ ion of  boldione, boldenone, androsta-1,4,6-triene-3,17-
dione (M5), (5α)-1-androstenedione (M6), (5α)-1-testosterone,(M8) and (5β)-1-testosterone (M9), 
available as standards..  
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(5α)-1-androstenedione (M6), CE 20 eV 
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Figure 3. Product ion mass spectra of [M+H]+ ion of  metabolites M1, M2, M3, M4, M7, M10, M11 and 
M12. 
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Metabolite M4 
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Figure 4. SRM Chromatograms of the transition m/z 283 to m/z 97 characteristic of metabolites M4 (RT 
4.1 min) and M5 (RT 4.9 min) in the free fraction (bottom) and in the alkaline fraction (top) in samples 
collected before administration and 2 and 5 days after boldione administration. 
 
Pre-administration 2 days after administration 5 days after administration 
 
 
 
 
 
 
 
 
